x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243146
| Product Information | |
|---|---|
| CAS No. | 1256756-88-3 |
| Synonyms | SP2086 phosphate |
| Formula | C19H21F6N4O7P |
| Molecular Weight | 562.36 |
| SMILES | O=C(C1=C2CN(C(C[C@H](N)CC3=CC(F)=C(F)C=C3F)=O)CCN2C(C(F)(F)F)=N1)OC.O=P(O)(O)O |
| Target | Dipeptidyl Peptidase |
| Product Description | Retagliptin phosphate (SP2086 phosphate) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin phosphate can be used for type 2 diabetes mellitus (T2DM) research. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Color | White to light yellow |
| Purity | 99.89% |
| Shipping | Room temperature in the continental U.S. Other areas may vary. |
| Storage | In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
